Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 4/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | TNF | P01375 | 1/20 | 0.47 |
| ▸ | MDM4 | O15151 | 2/20 | 0.46 |
| ▸ | TP53 | P04637 | 2/20 | 0.46 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.45 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.45 |
| ▸ | MMP9 | P14780 | 1/20 | 0.44 |
| ▸ | MMP8 | P22894 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29908049 | 1.00 | CASP3 (0.49) | CASP3KMT2ATNFMDM4TP53 | |
| SCHEMBL7713563 | 1.00 | CASP3 (0.49) | CASP3KMT2ATNFMDM4TP53 | |
| SCHEMBL31606673 | 1.00 | CASP3 (0.49) | CASP3KMT2ATNFMDM4TP53 | |
| SCHEMBL7713562 | 1.00 | CASP3 (0.49) | CASP3KMT2ATNFMDM4TP53 | |
| SCHEMBL15521327 | 1.00 | CASP3 (0.49) | CASP3KMT2ATNFMDM4TP53 | |
| SCHEMBL22433817 | 1.00 | CASP3 (0.49) | CASP3KMT2ATNFMDM4TP53 | |
| SCHEMBL29400370 | 0.89 | CASP3 (0.51) | CASP3KMT2AMDM4TP53PIN1 | |
| SCHEMBL27128404 | 0.89 | CASP3 (0.51) | CASP3KMT2AMDM4TP53PIN1 | |
| SCHEMBL27028719 | 0.89 | CASP3 (0.51) | CASP3KMT2AMDM4TP53PIN1 | |
| SCHEMBL29447741 | 0.89 | CASP3 (0.46) | CASP3KMT2AMDM4TP53PIN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12612429-B2 | Derivatives of dolaproine-dolaisoleuine peptides | AGENSYS, INC. (US) | 2026-04-28 | — | — | US | disclosed |
| US-20260091082-A1 | CYCLIC PEPTIDE DERIVATIVE COMPOSITION FOR TREATING OR PREVENTING EYE DISEASE | DKS CO. LTD. (JP) | 2026-04-02 | — | — | US | disclosed |
| US-20260035407-A1 | CYCLIC PEPTIDE DERIVATIVE, METHOD FOR PRODUCING SAME, AND COMPOSITION | DKS CO. LTD. (JP) | 2026-02-05 | — | — | US | disclosed |
| EP-4646425-A1 | CASPASE-2 INHIBITOR COMPOUNDS | Kintsugi Therapeutics S.L. (ES) | 2025-11-12 | — | — | EP | disclosed |
| US-20250313594-A1 | TWO-RESIDUE-EXTENDED PEPTIDE AND METHOD FOR PRODUCING SAME | NATIONAL UNIVERSITY CORPORATION TOKAI NATIONAL HIGHER EDUCATION AND RESEARCH SYSTEM (JP) | 2025-10-09 | — | — | US | disclosed |
| EP-4613282-A1 | CYCLIC PEPTIDE DERIVATIVE COMPOSITION FOR TREATING OR PREVENTING CENTRAL NERVOUS SYSTEM INJURY/DISEASE | DKS Co. Ltd. (JP) | 2025-09-10 | — | — | EP | disclosed |
| US-20250270255-A1 | CASPASE-2 INHIBITOR COMPOUNDS | KINTSUGI THERAPEUTICS S L (ES) | 2025-08-28 | — | — | US | disclosed |
| EP-4595973-A1 | CYCLIC PEPTIDE DERIVATIVE COMPOSITION FOR TREATING OR PREVENTING EYE DISEASE | DKS Co. Ltd. (JP) | 2025-08-06 | — | — | EP | disclosed |
| EP-4567042-A1 | CYCLIC PEPTIDE DERIVATIVE, METHOD FOR PRODUCING SAME, AND COMPOSITION | DKS Co. Ltd. (JP) | 2025-06-11 | — | — | EP | disclosed |
| EP-4556467-A2 | METHODS FOR ARRAY SYNTHESIS | Vibrant Holdings, LLC (US) | 2025-05-21 | — | — | EP | disclosed |
| US-6310040-B1 | FOR PROMOTING THE SURVIVAL OF PHOTORECEPTORS IN A MAMMAL | CEPHALON, INC. | 2001-10-30 | — | — | US | disclosed |
| US-5776897-A | Treating disorders by application of insulin-like growth factors and analogs | CEPHALON, INC. (US) | 1998-07-07 | — | — | US | disclosed |
| US-5703045-A | NERVOUS SYSTEM DISORDERS | CEPHALON, INC. (US) | 1997-12-30 | — | — | US | disclosed |
| US-5652214-A | ENHANCING SURVIVAL OF NEURONAL CELLS IN HEAD AND SPINAL CORD AFTER INJURY, ALSO TREATMENT OF AGING, ALZHEIMER*S, STROKE, EPILEPSY | CEPHALON, INC. (US) | 1997-07-29 | — | — | US | disclosed |
| EP-0604605-A4 | TREATING DISORDERS BY APPLICATION OF INSULIN-LIKE GROWTH FACTORS AND ANALOGS. | CEPHALON INC (US) | 1997-01-29 | — | — | EP | disclosed |
| EP-0670729-A1 | TREATING RETINAL NEURONAL DISORDERS BY THE APPLICATION OF INSULIN-LIKE GROWTH FACTORS AND ANALOGS | CEPHALON, INC. (US) | 1995-09-13 | — | — | EP | disclosed |
| EP-0670729-A4 | TREATING RETINAL NEURONAL DISORDERS BY THE APPLICATION OF INSULIN-LIKE GROWTH FACTORS AND ANALOGS. | CEPHALON INC (US) | 1995-05-10 | — | — | EP | disclosed |
| EP-0604605-A1 | TREATING DISORDERS BY APPLICATION OF INSULIN-LIKE GROWTH FACTORS AND ANALOGS | CEPHALON, INC. (US) | 1994-07-06 | — | — | EP | disclosed |
| WO-1993020836-A1 | TREATING DISORDERS BY APPLICATION OF INSULIN-LIKE GROWTH FACTORS AND ANALOGS | CEPHALON, INC. (US) | 1993-10-28 | — | — | WO | disclosed |
| WO-1993008826-A1 | TREATING RETINAL NEURONAL DISORDERS BY THE APPLICATION OF INSULIN-LIKE GROWTH FACTORS AND ANALOGS | CEPHALON, INC. (US) | 1993-05-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260091082-A1 | CYCLIC PEPTIDE DERIVATIVE COMPOSITION FOR TREATING OR PREVENTING EYE DISEASE | ADCY3, GLP1R, PDE6C | CASP3 305/4885KMT2A 4849/4885TNF 1617/4885 |
| US-20250270255-A1 | CASPASE-2 INHIBITOR COMPOUNDS | CASP2, CASP1, CASP3 | CASP3 3/4885KMT2A 2998/4885TNF 514/4885 |
| US-20260035407-A1 | CYCLIC PEPTIDE DERIVATIVE, METHOD FOR PRODUCING SAME, AND COMPOSITION | BDNF, VIP, CA3 | CASP3 214/4885KMT2A 3145/4885TNF 2404/4885 |
| US-12612429-B2 | Derivatives of dolaproine-dolaisoleuine peptides | DDOST, NGLY1, GRPR | CASP3 3315/4885KMT2A 4768/4885TNF 4296/4885 |
| US-20250313594-A1 | TWO-RESIDUE-EXTENDED PEPTIDE AND METHOD FOR PRODUCING SAME | NPPA, NGLY1, ANPEP | CASP3 1700/4885KMT2A 351/4885TNF 2462/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.